Figure 1.
First line (A), second line (B) and third line (C) treatment patterns and disposition of Canadian patients ineligible for high intensity chemotherapy. * Patients may be taking more than one systemic therapy simultaneously. AZA, 5-azacitidine; BSC, best supportive care; CA ± G, cytarabine, aclarubicin, G-CSF regimen; G-CSF, Granulocyte—colony stimulating factor; LDAC, low-dose cytarabine; VEN, venetoclax.
